Roche and Seaside Therapeutics Collaborate to Develop Disease-Modifying Therapies for Neurodevelopmental Disorders
By Heather Cartwright
Pharma Deals Review: Vol 2012 Issue 7 (Table of Contents)
Published: 2 Jul-2012
DOI: 10.3833/pdr.v2012.i7.1763 ISSN: 1756-7874
Section: Licensing
Fulltext:
Abstract
In a mutually beneficial deal, Roche has partnered with Seaside Therapeutics to develop disease-modifying therapies for neurodevelopmental disorders such as Fragile X syndrome (FXS) and autism spectrum disorders (ASD)...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS